Abstract | BACKGROUND: METHODS: Eligible patients had recurrent SCLC after a response to first-line chemotherapy. Stage 1 safety evaluation was completed with planned expansion if 9 responses were confirmed in the first 35 patients. Patients were treated every 21 days until progression or intolerable adverse events (AEs). RESULTS: Thirty-six patients were enrolled from 1998 to 2000. Neutropenia was the major toxicity, occurring in 26 of 36 patients (72%). Neutropenia was more severe (30% vs 20% grade 4) and developed earlier (58% vs 38% in Cycle 1) among the 15 patients who were enrolled prior to an amendment that required neutropenia prophylaxis. Four patients died on study: 2 from infections likely related to therapy and 2 from cancer progression. Seven of 36 patients (19%) had partial responses; 6 patients sustained responses through 6 cycles of treatment, with 1 response lasting 3 years. Three additional patients had unconfirmed responses, and 4 patients had stable disease. The median survival was 6 months. No correlative (99m)Tc-sestamibi uptake in tumor tissue was observed with the addition of VX-710 in this study. CONCLUSIONS: The addition of VX-710 to doxorubicin and vincristine therapy did not significantly enhance antitumor activity or survival. Although there were durable responses, criteria were not met to proceed with Stage 2 expansion.
|
Authors | Leena Gandhi, Matthew W Harding, Marcus Neubauer, Corey J Langer, Melvin Moore, Helen J Ross, Bruce E Johnson, Thomas J Lynch |
Journal | Cancer
(Cancer)
Vol. 109
Issue 5
Pg. 924-32
(Mar 01 2007)
ISSN: 0008-543X [Print] United States |
PMID | 17285598
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
- Piperidines
- Pyridines
- biricodar
- Vincristine
- Doxorubicin
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Small Cell
(drug therapy)
- Doxorubicin
(administration & dosage, adverse effects)
- Drug Resistance, Multiple
- Female
- Humans
- Lung Neoplasms
(drug therapy)
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Piperidines
(administration & dosage, adverse effects)
- Pyridines
(administration & dosage, adverse effects)
- Vincristine
(administration & dosage, adverse effects)
|